In the complex world of children’s cancer research, no independent organization currently coordinates efforts between academic scientists, drug developers, and policy regulators to advance new treatments and cures. Moving forward, CureSearch is proud to play the role of convener and collaborator to bring these key parties together in a way that is singularly focused on accelerating the commercialization of children’s cancer treatments to save children now.
Through this ground-breaking initiative, Catapult will propel discoveries over the Valley of Death. We hosted Phase One of the project, The Catapult Summit, on February 28 and 29, 2016 in Menlo Park, California, the home of some of the world’s most innovative advancements in medical research. A private and strategically curated event, Catapult Summit participants represent academia, industry, policy regulation, private foundations, and parents. All are leaders in the fight to end children’s cancer.
We are pleased with the progress we’ve made so far and grateful for the support of our generous donors and pharmaceutical industry partners. But there is much more to do. Please join us in advancing our shared goal – to find solutions that move promising new cancer treatments and cures out of the academic lab and into clinical trials.
The Catapult Fund
CureSearch for Children’s Cancer is pleased to launch Phase Two of CureSearch Catapult – the Catapult Fund. The Catapult Fund will provide funding support (as requested up to $1- 2M) for “clinic-ready” projects that fit the following parameters:
Phase 1 and Phase 2 human clinical trials: Proposed trials to test novel agents or combinations of agents or therapies. Trials to be considered may also utilize genomic, epigenetic and other molecular “omics” approaches for clinical marker discovery and clinical validation that will translate into diagnosis, prognosis and improved treatment of oncologic disease. All human trial protocols should include design elements that would generate data establishing both a “proof of principle” of human clinical activity, as well as to enable the testing of the technology in pediatric cancer patients.
For compelling “first in human” clinical studies, no more than 12 months of funding will be considered specifically to support pharmacodynamic, pharmacokinetic and/or non-human safety and toxicology studies. Continued funding will be dependent on meeting these milestones within the proposed timeline.
This grant opportunity is funded by CureSearch for Children’s Cancer to support the development of innovative, novel, and promising oncology research into human clinical trials and product commercialization with the ultimate goal of improving clinical outcomes in childhood cancer patients. CureSearch has particular interest in collaborative projects and/or research that leverage existing regulatory guidelines or governmental programs that require or reward research in the development of new therapies for pediatric patients.
The application window opens Monday, July 11, 2016 via Proposal Central, with award notifications released in February 2017. Funding will be provided 1 to 2 years, depending on the project. The complete Request for Applications is available here.
For more information about this grant opportunity or pediatric cancer research sponsored by CureSearch for Children’s Cancer, contact Sarita Sastry, PhD, National Director, Research and Programs, (240) 235-2215, email@example.com.
To learn more about the CureSearch Catapult Initiative, please contact Tess Mattingly, Director, Industry Partnerships, (240) 235-2230, firstname.lastname@example.org.